How do you manage moderately severe RLS in a patient with advanced CKD (eGFR 15–30) who has developed dopaminergic augmentation on a dopamine agonist, given that standard gabapentinoid replacement agents carry significant accumulation risk at this level of renal impairment?
How do you manage moderately severe RLS in a patient with advanced CKD (eGFR 15–30) who has developed dopaminergic augmentation on a dopamine agonist, given that standard gabapentinoid replacement agents carry significant accumulation risk at this level of renal impairment? | Mednet
